Loading patent…
AssigneePharmacia Italia S.p.A.
InventorsTiziano Bandiera, Paola Vianello, Paolo Cozzi, Arturo Galvani
Estimating the term…
Novel propanoic acid derivatives are integrin receptor antagonists or inhibitors, in particular of the avb3 integrin receptor. The compounds of the invention are for instance useful for the treatment of solid tumors by inhibition of angiogenic growth of tumor vessel network, thus promoting tumor regression, inhibition of metastatic spread, thus avoiding cancer metastases, inhibition of bone resorption, thus controlling osteoporosis, inhibition of smooth muscle cells migration into neointima, thus blocking restenosis after percutaneous coronary angioplasty and the treatment of other pathological conditions mediated by cell adhesion, cell migration or angiogenesis such e.g. diabetic retinopaty, rheumatoid arthritis and inflammation.
A compound which is a non-peptide of the following formula (I)
A compound selected from the group consisting of:
A compound which is a non-peptide of formula (I)
A method for treating a condition mediated by the αvβ3 integrin in a mammal in need of such treatment, including a human, comprising administering to said mammal an effective αvβ3 inhibiting or antagonizing amount of a compound which is a non-peptide of formula (I)
A combined method of treatment of cancer or of controlling the growth of a neoplasm in a mammal suffering from cancer, including a human, said method comprising administering simultaneous, separately or sequentially,
A product containing a compound which is a non-peptide of formula (I)
The use of a compound which is a non-peptide of formula (I)
Dependencies are inferred from the claim text.